| Serial Number | 99192534 |
| Word Mark | REDUCE-IT |
| Filing Date | Monday, May 19, 2025 |
| Status | 661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED |
| Status Date | Thursday, April 2, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| Pseudo Mark | REDUCE IT |
| Goods and Services | Providing medical research information in the field of pharmaceuticals, namely, information regarding a medical study on cardiovascular risk reduction with icosapent ethyl |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, May 19, 2025 |
| Primary Code | 042 |
| First Use Anywhere Date | Monday, September 24, 2018 |
| First Use In Commerce Date | Monday, September 24, 2018 |
| Party Name | Amarin Pharmaceuticals Ireland Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | Dublin D02EF64 IE |
| Event Date | Event Description |
| Monday, May 19, 2025 | NEW APPLICATION ENTERED |
| Monday, May 19, 2025 | APPLICATION FILING RECEIPT MAILED |
| Thursday, September 25, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, October 1, 2025 | ASSIGNED TO EXAMINER |
| Tuesday, October 7, 2025 | NON-FINAL ACTION WRITTEN |
| Tuesday, October 7, 2025 | NON-FINAL ACTION E-MAILED |
| Tuesday, October 7, 2025 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, December 31, 2025 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Wednesday, December 31, 2025 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Thursday, April 2, 2026 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, April 2, 2026 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, April 2, 2026 | TEAS/EMAIL CORRESPONDENCE ENTERED |